Patient-Specific Quality Assurance of Volumetric Modulated Arc Therapy (VMAT): Amorphous Silicon Type Compared with Diode 3D Array Phantom

Authors

  • Somsak Khuanchana National Cancer Institute
  • Kananan Utitsarn Lopburi Cancer Hospital
  • Wirasinee Chaloemchawalit Lopburi Cancer Hospital
  • Komkrit Krongkietlearts Lopburi Cancer Hospital

Keywords:

Volumetric Modulated Arc Therapy (VMAT), Pre-Treatment QA Tool, Diode 3D Array Phantom, Amorphous Silicon Type

Abstract

Purpose: To compare the results of amorphous silicon pre-treatment QA type and  diode 3D array phantom for delivery pre-treatment quality assurance of head and neck and   prostate Volumetric Modulated Arc Therapy (VMAT) with various gamma criteria evaluation. Materials and Methods: The Varian amorphous silicon (aSi) Portal Imaging Devices and its software was used for portal dosimetry system (PDs). A diode 3D array cylindrical phantom (ArcCheck) was used for the studies. Eclipse-TPS with VMAT treatment planning and portal  dose prediction software was used for planar dose calculations. The 30 VMAT patient plans   of head and neck site and prostate site from the radiotherapy department, Lopburi Cancer  Hospital, were created for verification plan on two different QA system PDs and ArcCheck.Thirty patients' treatment plans, each with 2 or 3 arcs, were delivered on the EPIDs of the Varian Linac iX (PDs) and ArcCheck, respectively. The measured planar dose matrices were  compared with the planned dose and analysed using global gamma evaluation with  3%/3mm, 3%/2mm, and 2%/2mm. Results: All head and neck plans measured by PDs and ArcCheck had the average passing rate using 3%/3mm of 97.91%±0.93 and 97.81%±0.81, respecttively. When using 3%/2mm and 2%/2mm, the average passing rate measured   by PD was 95.65%±0.83 and 76.48±2.55, while the results measured by ArcCheck were 96.63% ± 0.77 and 79.77±2, respectively. All prostate plans measured by PDs and ArcCheck using            3%/3 mm criteria have the average gamma passing rate of 99.10±0.86 and 99.56±0.47, respectively. The average gamma passing rate when using 3%/2mm was 98.11%±1.02 for PD    and 98.67% ± 0.90 for ArcCheck, while the passing rate decreased to 97.05%±0.82 for PD and 97.46%±0.68 for ArcCheck when using 2%/2mm.The prostate cases illustrated no significant difference for all gamma criteria with a P-value greater than 0.05. Conclusion: The PDs system  and ArcCheck can be considered QA tools for the verification plan of VMAT. The results of  planning verification were comparable for the criteria of 3%/3mm and 3%/2mm.

References

Teoh M., Clark C. H., Wood K., et al.Volumetric modulated arc therapy: A review of current literature and clinical use in practice. Br. J. Radiol 2011;84:967–96.

Kuijper I. T., Dahele M., Senan S.,et al. Volumetric modulated arc therapy versus conventional intensity modulated radiation therapy for stereotactic spine radiotherapy: A planning study and early clinical data. Radiother Oncol 2010;94:224–28.

Schreibmann E., Dhabaan A., Elder E., et al. Patient-specific quality assurance method for VMAT treatment delivery. Med Phys 2009;36:4530–35.

Mijnheer B., Jomehzadeh A.,González P.,et al.Error detection during VMAT delivery using EPID-based 3D transit dosimetry. Phys Medica 2018;54:137–45.

Thiyagarajan R.,Nambiraj A,Sinha Nath S., et al. Analyzing the performance of ArcCHECK diode array detector for VMAT plan. Reports Pract Oncol Radiother 2016;21:50–6.

Aristophanous M., Suh Y., Chi P. C., et al. Initial clinical experience with ArcCHECK for IMRT/VMAT QA. J Appl Clin Med Phys 2016;17:20–33.

Li G., Zhang Y.,Jiang X.,et al.Evaluation of the ArcCHECK QA system for IMRT and VMAT verification.Phys medica 2013;29:295–303.

Chaswal V., Weldon M., Gupta N., et al. Commissioning and comprehensive evaluation of the ArcCHECK cylindrical diode array for VMAT pretreatment delivery QA. J Appl Clin Med Phys 2014;15:212–25.

Dosimetry W. P. Portal Dosimetry Fast , convenient IMRT QA with Portal Dosimetry from Varian Medical Fast. J Appl Clin Med Phy 2012;13: 82–99.

Iori M., Cagni E., Paiusco M.,et al .Dosimetric verification of IMAT delivery with a conventional EPID system and a commercial portal dose image prediction tool . Med Phys 2010;37:377–90.

Bailey D. W., Kumaraswamy L., Bakhtiari M., et al . EPID dosimetry for pretreatment quality assurance with two commercial systems. J Appl Clin Med Phys 2012;13: 82–99.

Krishna K. Murthy. Patient-specific quality assurance of RapidArc treatments: Portal prediction dosimetry compared with phantom studies. Biomed Imaging Interv J 2012;8:45-49.

Low D. A., Harms W. B., Mutic S.,et al. A technique for the quantitative evaluation of dose distributions.Med Phys 1998;25:656–61.

Mihailidis D., Molineu A., Palta J. R.. IMRT commissioning: multiple instruction planning and dosimetry compaisons, a report from AAPM task Group 119. Med Phys 2009; 36 (11): 36 (11):5359-73.

Heilemann G., Poppe B., Laub W..On the sensitivity of common gamma-index evaluation methods to MLC misalignments in Rapidarc quality assurance. Med Phys 2013;40:1–12.

Kim in J., Park S. Y., Kim H. J., et al.The sensitivity of gamma-index method to the positioning errors of high-definition MLC in patient-specific VMAT QA for SBRT. Radiat Oncol 2014;9:1–12.

Van Esch A. Depuydt T.,Huyskens D.P. The use of an aSi-based EPID for routine absolute dosimetric pre-treatment verification of dynamic IMRT fields. Radiother Oncol 2004;8:223–34.

Gary A, Ezzell JWB, Nesrin D, et.al. IMRT commissioning: Multiple institution planning and dosimetry comparison, a report from AAPM task Group 119. Med Phys 2012; 36:5359-73.

Mynampati DK, Yaparpalvi R, Hong L, et Al. Application of AAPM TG 119 to Volumetric Arc Therapy(VMAT), a report from AAPM task Group 119. Med Phys 2012; 13:108-16.

Downloads

Published

2022-04-29